Published in World J Gastroenterol on April 01, 2001
The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol (2002) 2.03
Chronic viral hepatitis and hepatocellular carcinoma. World J Surg (2007) 1.62
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer (2005) 1.51
The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 1.27
High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol (2002) 1.25
Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol (2002) 1.19
Effects of hepatitis B virus infection on human sperm chromosomes. World J Gastroenterol (2003) 1.07
Prevalence of hepatitis B and C markers among refugees in Athens. World J Gastroenterol (2003) 1.03
Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol (2007) 1.03
Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res (2007) 0.98
Local recurrence is an important prognostic factor of hepatocellular carcinoma. World J Gastroenterol (2005) 0.97
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line. World J Gastroenterol (2002) 0.89
Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon (2012) 0.87
Safe upper limit of intermittent hepatic inflow occlusion for liver resection in cirrhotic rats. World J Gastroenterol (2001) 0.87
Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol (2005) 0.87
Applying a highly specific and reproducible cDNA RDA method to clone garlic up-regulated genes in human gastric cancer cells. World J Gastroenterol (2002) 0.86
Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med (2010) 0.86
Fos expression in tyrosine hydroxylase-containing neurons in rat brainstem after visceral noxious stimulation: an immunohistochemical study. World J Gastroenterol (2003) 0.86
Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol (2004) 0.86
Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol (2004) 0.85
Gene expression profiles of hepatoma cell line HLE. World J Gastroenterol (2003) 0.83
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol (2014) 0.83
Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation. J Cancer Res Clin Oncol (2008) 0.83
Effects of Zhaoyangwan on chronic hepatitis B and posthepatic cirrhosis. World J Gastroenterol (2004) 0.82
Preparation of monoclonal antibody against apoptosis-associated antigens of hepatoma cells by subtractive immunization. World J Gastroenterol (2002) 0.81
Construction of HCV-core gene vector and its expression in cholangiocarcinoma. World J Gastroenterol (2002) 0.81
Glycylproline dipeptidyl aminopeptidase isoenzyme in diagnosis of primary hepatocellular carcinoma. World J Gastroenterol (2003) 0.80
Establishment of mice model with human viral hepatitis B. World J Gastroenterol (2004) 0.79
Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity. World J Gastroenterol (2003) 0.78
Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J Gastroenterol (2013) 0.78
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol (2012) 0.77
Role of preoperative selective portal vein embolization in two-step curative hepatectomy for hepatocellular carcinoma. World J Gastroenterol (2003) 0.77
Preparation and characterization of polyclonal antibodies against ARL-1 protein. World J Gastroenterol (2003) 0.77
Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med (2012) 0.76
Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice. World J Gastroenterol (2004) 0.76
Construction and expression of recombined human AFP eukaryotic expression vector. World J Gastroenterol (2003) 0.75
Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients: A UNOS database analysis. BMC Anesthesiol (2016) 0.75
Lethiferous effects of a recombinant vector carrying thymidine kinase suicide gene on 2.2.15 cells via a self-modulating mechanism. World J Gastroenterol (2003) 0.75
Surgical resection of recurrent extrahepatic hepatocellular carcinoma with tumor thrombus extending into the right atrium under cardiopulmonary bypass: a case report and review of the literature. Surg Case Rep (2016) 0.75
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 7.05
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology (1995) 2.85
Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med (2000) 2.67
Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg (1993) 2.06
Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol (1996) 2.02
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology (2000) 1.95
Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol (2000) 1.73
The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature (1990) 1.69
The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer (1992) 1.68
Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem (1997) 1.54
Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene (1998) 1.50
Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust (2000) 1.50
Glucose resistance contributes to diabetes mellitus in cirrhosis. Hepatology (1993) 1.49
Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer (1999) 1.43
Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol (1999) 1.38
Improved survival with screening for hepatocellular carcinoma. Liver Transpl (2000) 1.37
Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol (1998) 1.33
A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci U S A (1990) 1.27
A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int J Epidemiol (1998) 1.19
Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet (1992) 1.17
Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer (1999) 1.17
Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. Ann Surg (1999) 1.09
Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev (2000) 1.08
Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J Hepatol (1996) 1.08
Hepatitis B carriage explains the excess rate of hepatocellular carcinoma for Maori, Pacific Island and Asian people compared to Europeans in New Zealand. Int J Epidemiol (1999) 1.06
Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. Int J Cancer (1998) 1.03
Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. Biochem Biophys Res Commun (1996) 1.03
A comparison of hepatocellular carcinoma associated with HBV or HCV infection. Hepatogastroenterology (1999) 1.02
Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control (2000) 1.01
Chronic liver diseases for the risk of hepatocellular carcinoma: a case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology (1999) 1.00
Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer (1997) 0.99
Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol Hepatol (2000) 0.99
A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control (1999) 0.97
Carcinogenesis of primary liver malignancies. Langenbecks Arch Surg (2000) 0.96
Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis. Adv Virus Res (1996) 0.95
Survival and causes of death in hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci (1988) 0.93
Trends in mortality from primary liver cancer in Europe. Eur J Cancer (2000) 0.93
Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology (1998) 0.92
[Percutaneous interstitial thermotherapy of malignant liver tumors]. Rofo (2000) 0.91
Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol (1998) 0.90
Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver (2000) 0.88
Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery (1998) 0.86
[Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic]. Z Gastroenterol (1997) 0.84
Liver cancer among employees in Denmark. Am J Ind Med (1997) 0.82
Hepatocellular carcinoma in Sweden: its association with viral hepatitis, especially with hepatitis C viral genotypes. Scand J Infect Dis (2000) 0.82
Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol (2000) 0.82
Primary hepatic cancer and liver cirrhosis. Autopsy study covering fifty years. Hepatogastroenterology (1984) 0.80
Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. J Cancer Res Clin Oncol (1998) 0.80
[International registry of liver tumors in liver transplantation. A registry update on hepatocellular carcinoma (HCC)]. Zentralbl Chir (2000) 0.79
Radiofrequency ablation in the treatment of hepatocellular carcinoma--a clinical viewpoint. J Hepatol (2000) 0.79
[Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis]. Z Gastroenterol (1999) 0.79
Percutaneous ethanol injection under general anesthesia for hepatocellular carcinoma: 3 year survival in 112 patients. Eur J Ultrasound (1998) 0.79
Interaction of Hepatitis B virus with cellular processes in liver carcinogenesis. Crit Rev Clin Lab Sci (2000) 0.77
The epidemiology of primary liver cancer in a West German population: the Saarland. J Cancer Res Clin Oncol (1986) 0.77
The incidence of hepatocellular carcinoma in New Zealand. N Z Med J (1998) 0.77
Epidemiology of hepatocellular carcinoma. Evaluation of viral and other risk factors in a low-endemic area for hepatitis B and C. Z Gastroenterol (1994) 0.77
High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepatogastroenterology (1999) 0.77
Most of the patients with cirrhosis in Japan die from hepatocellular carcinoma. Oncol Rep (1999) 0.77
Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan. Antivir Ther (1998) 0.77
Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology (1999) 6.50
Shock-wave lithotripsy of gallbladder stones. The first 175 patients. N Engl J Med (1988) 5.53
Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med (1986) 2.76
Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol (2002) 2.54
A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut (1997) 2.32
Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest (1998) 2.12
Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol (1989) 2.09
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Clostridium difficile infection in patients with neutropenia. Clin Infect Dis (2001) 2.00
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. Support Care Cancer (2002) 1.95
Dacryoliths: nonsurgical fluoroscopically guided treatment during dacryocystoplasty. Radiology (1999) 1.89
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology (1996) 1.88
Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology (2000) 1.82
Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology (1997) 1.79
Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol (1998) 1.78
Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol (2007) 1.76
Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology (1992) 1.70
Dormia baskets impacted in the bile duct: release by extracorporeal shock-wave lithotripsy. Endoscopy (1995) 1.70
The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature (1990) 1.69
Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest (1999) 1.68
Comparison of capsule endoscopy and magnetic resonance imaging for the detection of polyps of the small intestine in patients with familial adenomatous polyposis or with Peutz-Jeghers' syndrome. Endoscopy (2004) 1.64
Gallstones: pathogenesis. Lancet (1991) 1.64
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol (2011) 1.62
Gallstone recurrence after shock-wave therapy. Gastroenterology (1994) 1.59
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Dysembryoplastic neuroepithelial tumors: MR and CT evaluation. AJNR Am J Neuroradiol (1996) 1.53
Differential antigen-processing pathways of the hepatitis B virus e and core proteins. Gastroenterology (1999) 1.52
Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. Radiology (1997) 1.52
Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy (2002) 1.51
Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem (2001) 1.50
Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. Gastroenterology (1991) 1.47
Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. Am J Gastroenterol (2000) 1.46
[Symptoms, tumor stage and primary treatment in patients with colorectal carcinoma]. Dtsch Med Wochenschr (1997) 1.46
Positional venous MR angiography: an operator-independent tool to evaluate cerebral venous outflow hemodynamics. AJNR Am J Neuroradiol (2011) 1.44
Proton magnetic resonance spectroscopy in Kennedy syndrome. Arch Neurol (1999) 1.44
Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J (1992) 1.43
Surgical intervention following fragmentation of gallstones by extracorporeal shock waves. World J Surg (1989) 1.42
[Fecal incontinence]. Internist (Berl) (2000) 1.42
Serum bile acids: physiology and clinical relevance. Eur J Gastroenterol Hepatol (1995) 1.41
[Therapy-refractory thrombocytopenia in chronic hepatitis C]. Z Gastroenterol (2000) 1.39
[The therapy of the hepatorenal syndrome in liver cirrhosis]. Dtsch Med Wochenschr (1999) 1.39
Treatment of benign prostatic hyperplasia by occlusion of the impaired urogenital venous system - first experience. Rofo (2014) 1.39
Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J Clin Oncol (2002) 1.37
Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother (1999) 1.33
Dynamic image interpretation of MRI of the breast. J Magn Reson Imaging (2000) 1.33
Do T2-weighted pulse sequences help with the differential diagnosis of enhancing lesions in dynamic breast MRI? J Magn Reson Imaging (1999) 1.32
Mixed-strain infection with a drug-sensitive and multidrug-resistant strain of Mycobacterium tuberculosis. Lancet (1995) 1.32
Mutations in the gene encoding the Wnt-signaling component R-spondin 4 (RSPO4) cause autosomal recessive anonychia. Am J Hum Genet (2006) 1.30
A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther (2001) 1.28
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol (2000) 1.28
MR imaging--guided large-core (14-gauge) needle biopsy of small lesions visible at breast MR imaging alone. Radiology (2001) 1.28
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol (1995) 1.27
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology (2001) 1.25
Mechanisms of extrahepatic vasodilation in portal hypertension. Gut (2008) 1.23
The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. Ann Intern Med (1991) 1.23
Diffusion tensor pyramidal tractography in patients with anterior choroidal artery infarcts. AJNR Am J Neuroradiol (2007) 1.22
Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother (2001) 1.21
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol (1999) 1.20
Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant (2005) 1.20
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology (1992) 1.19
A retrospective analysis of 3 year's experience of an interdisciplinary approach to gallstone disease including shock-waves. Ann Surg (1988) 1.19
Shock-wave therapy of gastric outlet syndrome caused by a gallstone. Gastroenterology (1989) 1.19
Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology (1995) 1.17
Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (1996) 1.16
Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy (2009) 1.16
Intestinal involvement in progressive systemic sclerosis detected by increased unconjugated serum bile acids. Gut (1987) 1.14
Detectability and detection rate of acute cerebral hemisphere infarcts on CT and diffusion-weighted MRI. Neuroradiology (2000) 1.14
Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem (2000) 1.13
Combined intrauterine and ovarian pregnancy mimicking ovarian malignant tumor: imaging findings. AJR Am J Roentgenol (1995) 1.13
Middle cerebral artery (MCA) susceptibility sign at susceptibility-based perfusion MR imaging: clinical importance and comparison with hyperdense MCA sign at CT. Radiology (2000) 1.11
Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet (1986) 1.11
Littoral cell angioma as a rare cause of splenomegaly. Ann Hematol (2001) 1.11
Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol (1996) 1.10
Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology (2000) 1.10
Endoscopy in the diagnosis of gastritis. Diagnostic value of endoscopic criteria in relation to histological diagnosis. Endoscopy (1984) 1.10
Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging (2013) 1.08
CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol (1997) 1.08
Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy (2002) 1.07
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol (2009) 1.07
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression. Clin Exp Immunol (2001) 1.07
Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol (2006) 1.06
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis (2006) 1.06
Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology (1990) 1.06
Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol (1999) 1.06
"Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology (2000) 1.06
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses (1999) 1.06
Integrated hepatitis B virus X and 3' truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene (1994) 1.06
Esophageal function after sclerotherapy of bleeding varices. Scand J Gastroenterol (1982) 1.05
Detection of thrombosis in the portal venous system: comparison of contrast-enhanced MR angiography with intraarterial digital subtraction angiography. Radiology (2000) 1.03
Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica (2001) 1.02